Cellular Biomedicine Group, a developer of cell therapies for the treatment of degenerative diseases, has completed patient enrollment in its Phase I trial to evaluate the safety and preliminary efficacy of TC-DC, or tumor stem cell specific dendritic cell, therapy for hepatocellular carcinoma, or HCC.
http://technews.tmcnet.com/news/2013/08/30/7377856.htm
http://technews.tmcnet.com/news/2013/08/30/7377856.htm
No comments:
Post a Comment